کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
6103668 | 1211131 | 2014 | 7 صفحه PDF | دانلود رایگان |
Background & AimsPatients with genotype 3 hepatitis C virus (HCV) infection and cirrhosis have poor response rates after 24Â weeks treatment with pegylated interferon and ribavirin. Treatment for 48Â weeks is therefore recommended, although the benefits of this are untested. We examined extended therapy in patients with genotype 3 HCV and advanced fibrosis.MethodsMulticentre, open labelled randomized trial comparing therapy with 24Â weeks pegylated interferon and ribavirin to 48Â weeks of the same therapy.Results136 patients completed the study. 67 received 24Â weeks therapy and the SVR rate (48%) did not differ from that seen in the 69 patients who received 48Â weeks therapy (42%). The response rates in patients with biopsy proven cirrhosis (13 patients treated for 24Â weeks, 18 patients treated for 48Â weeks) or cirrhosis proven on imaging (28 patients treated for 24Â weeks and 25 patients treated for 48Â weeks) were 46% in those treated for 24Â weeks and 40% in those treated for 48Â weeks. The differences were not significantly different. Treatment failure was due to relapse in the majority of patients.ConclusionsPatients with genotype 3 HCV and advanced fibrosis do not benefit from extended therapy with pegylated interferon and ribavirin.
Journal: Journal of Hepatology - Volume 60, Issue 4, April 2014, Pages 699-705